



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.								
09/661,693	09/14/2000	Sathasivan Indiran Pather	CIMA 3.0-030 CONT II	2096								
57339 CIMA LERNER, DAVID ET AL 600 SOUTH AVENUE WEST WESTFIELD, NJ 07090	7590 04/16/2007		<table border="1"><tr><td colspan="2">EXAMINER</td></tr><tr><td colspan="2">RAMACHANDRAN, UMAMAHESWARI</td></tr><tr><td>ART UNIT</td><td>PAPER NUMBER</td></tr><tr><td colspan="2">1617</td></tr></table>		EXAMINER		RAMACHANDRAN, UMAMAHESWARI		ART UNIT	PAPER NUMBER	1617	
EXAMINER												
RAMACHANDRAN, UMAMAHESWARI												
ART UNIT	PAPER NUMBER											
1617												
SHORTENED STATUTORY PERIOD OF RESPONSE		MAIL DATE	DELIVERY MODE									
3 MONTHS		04/16/2007	PAPER									

Please find below and/or attached an Office communication concerning this application or proceeding.

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.

Office Action Summary

Application No.

09/661,693

Applicant(s)

PATHER ET AL.

Examiner

Umamaheswari Ramachandran

Art Unit

1617

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 08 January 2007.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 22, 25-27, 30-33, 83, 84, 86, 88, 91, 93 and 94 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 22, 25-27, 30-33, 83, 84, 86, 88, 91, 93 and 94 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
 - ☐ Certified copies of the priority documents have been received in Application No. _____.
 - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- ☒ Notice of References Cited (PTO-892)
- ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- ☐ Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date _____
- ☐ Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____
- ☐ Notice of Informal Patent Application
- ☐ Other: _____

DETAILED ACTION

Continued Examination Under 37 CFR 1.114

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 1/8/2007 has been entered.

Claims pending are 22, 25-27, 30-33, 83, 84, 86, 88, 91, 93 and 94. Claims 22 and 30 have been amended and claims 23 and 36 have been canceled.

Double Patenting

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 22, 25-27, 30-33, 83, 84, 86, 88, 91, 93 and 94 are provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-22 of copending Application No. 11/026,327 ('327). Although the conflicting claims are not identical, they are not patentably distinct from each other

Art Unit: 1617

because the presently claimed invention overlaps with that previously claimed.

Specifically, claims 1-22 of '327 are directed to a method of making the product claimed in the instant claims. The product claims of the instant invention are obvious over the claims directed to a method of making such product because the method claims of '327 recite the product claimed herein.

This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

Claims 22, 25-27, 30-33, 83, 84, 86, 88, 91, 93 and 94 are provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-30 of copending Application No. 111026,132 ('132)

The instant application teaches a tablet comprising fentanyl, at least one pH adjusting substance and saliva activated effervescent couple and the co-pending application '132 teaches a tablet comprising fentanyl, effervescent couple and pH adjusting substance.

Although the conflicting claims are not identical, they are not patentably distinct from each other because the presently claimed invention overlaps with that previously claimed. Thus, the copending application is directed to fentanyl, an effervescent dosage form, which anticipate the instantly claimed invention.

This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

Claims 22, 25-27, 30-33, 83, 84, 86, 88, 91, 93 and 94 are provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-30 of copending Application No. 111027,353 ('353).

The instant application teaches a tablet comprising fentanyl, at least one pH adjusting substance and saliva activated effervescent couple and the co-pending application '353 teaches a dosage form comprising fentanyl, an effervescent couple and pH adjusting substance.

Although the conflicting claims are not identical, they are not patentably distinct from each other because the presently claimed invention overlaps with that previously claimed. Thus, the copending application is directed to fentanyl, an effervescent dosage form, which anticipate the instantly claimed invention.

This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 22, 26, 27, 30-33, 83, 84, 86, 88, 91, 93 and 94 are rejected under 35 U.S.C. 103(a) as being unpatentable over McCarty (US 5,073,374) in view of Wehling et al. (WO 91104757) and further in view of Streisand et al. (Buccal absorption of fentanyl is pH-dependent in dogs', Anesthesiology, (1995 Mar), 82 (3), pp. 759-64).

McCarty teaches fast dissolving buccal tablets particularly useful for the administration of active ingredients that show poor bioavailability upon administration through non-parenteral modes (See Abstract). Such active ingredients include analgesics such as fentanyl (col. 1, lines 14-30). The tablets of McCarty are placed in the buccal pouch of the oral cavity and allowed to dissolve (col. 4, lines 3-7).

McCarty does not teach the effervescent couple of the instant claims.

Wehling et al. teach effervescent dosage forms for direct oral administration (i.e. for direct insertion into the mouth of a patient), which comprise at least one systemically distributable ingredient (e.g. a drug), effervescent disintegration agents (a soluble acid source and a carbonate source) and adjuvants such as binders, flavors, colors, fillers, non-effervescent disintegrants, etc. (p. 3, lines 30-37; p. 11, lines 22-38; p. 12, lines 1-19; p. 14, lines 25-37; p. 15). Analgesics are among the drugs that can be administered in oral effervescent dosage forms of Wehling et al. (p. 9, line 29). The amount of the effervescent disintegration agents is 5-50% by weight, and the amount of either acid or carbonate source may exceed the amount of the other component (p. 12, lines 20-36; p. 13, lines 3-12). "This may be useful to enhance taste and/or performance of a tablet containing an overage of either component" (p. 12, lines 36-38). The tablets of Wehling et al. dissolve in the mouth in between about 30 seconds and about 7 minutes (p. 13, lines 13-24). Wehling et al. teach that the use of the effervescent disintegration agents provides the following benefits: masking the objectionable flavor of medicaments, facilitating the disintegration of the tablet and providing pleasant organoleptic sensation (p. 6, lines 15-26). Further, such dosage forms are particularly useful in administration

Art Unit: 1617

of medications to patients who cannot or will not chew, such as children and the elderly (p. 4, lines 9-25).

Therefore, it would have been prima facie obvious to one having ordinary skill in the art at the time the invention was made to modify the fast dissolving buccal fentanyl tablets of McCarty such that to employ effervescent disintegration agents. One having ordinary skill in the art would have been motivated to do this to obtain even faster dissolution as well as masking the objectionable flavor of medicaments and providing pleasant organoleptic sensation as suggested by Wehling et al. Further, while suggesting that the amount of either acid or carbonate source may exceed the amount of the other component in order to enhance taste and/or performance of a tablet containing an overage of either component, the Wehling reference does not explicitly teach the at least one pH adjusting substance which is a base as claimed herein.

Streisand et al. teach that the buccal absorption, bioavailability and permeability of fentanyl are pH dependent and increase as the pH of the fentanyl solution becomes more basic, which is due to an increase in the fraction of unionized fentanyl (Abstract; Discussion).

Therefore, it would have been prima facie obvious to one having ordinary skill in the art at the time the invention was made to modify the teachings of Wehling et al. such as to employ the excess of the carbonate source (base). One having ordinary skill in the art would have been motivated to do this to obtain basic pH as which the buccal absorption, bioavailability and permeability of fentanyl increase, thus making the tablet more effective, as suggested by Streisand et al. With respect to Claims 93 and 94,

which recite tablet "adapted for" gingival and sublingual administration, respectively, these types of administration are obvious variations of oral transmucosal administration. Therefore, Claims 93 and 94 don't recite any additional ingredients and/or characteristics, therefore, the combination of references discussed above meets the claimed limitations.

Claims 22, 25-27, 30-33, 83, 84, 86, 88, 91, 93 and 94 are rejected under 35 U.S.C. 103(a) as being unpatentable over Chen et al. ('Studies on formulations of fentanyl buccal adhesive tablets', Zhongguo Yiyao Gongye Zazhi, 1997, 28(3), 129-1311) in view of Wehling et al. (WO 91104757) and further in view of Streisand et al. ('Buccal absorption of fentanyl is pH-dependent in dogs', Anesthesiology, (1995 Mar), 82 (3), pp. 759-64).

Chen et al. teach fentanyl citrate buccal adhesive tablets (see Abstract). Chen et al. do not teach the effervescent couple of the instant claims.

Wehling et al. teach effervescent dosage forms for direct oral administration as discussed above.

Streisand et al. teach that the buccal absorption, bioavailability and permeability of fentanyl are pH dependent and increase as the pH of the fentanyl solution becomes more basic as discussed above.

Therefore, it would have been prima facie obvious to one having ordinary skill in the art at the time the invention was made to modify the adhesive buccal fentanyl tablets of Chen et al. such that to employ effervescent disintegration agents. One having ordinary skill in the art would have been motivated to do this to obtain even

faster dissolution as well as masking the objectionable flavor of medicaments and providing pleasant organoleptic sensation as suggested by Wehling et al. Further, it would have been prima facie obvious to one having ordinary skill in the art at the time the invention was made to modify the teachings of Wehling et al. such as to employ the excess of the carbonate source (base). One having ordinary skill in the art would have been motivated to do this to obtain basic pH as which the buccal absorption, bioavailability and permeability of fentanyl increase, thus making the tablet more effective, as suggested by Streisand et al. With respect to Claims 93 and 94, which recite tablet "adapted for" gingival and sublingual administration, respectively, these types of administration are obvious variations of oral transmucosal administration. Therefore, Claims 93 and 94 don't recite any additional ingredients and/or characteristics, therefore, the combination of references discussed above meets the claimed limitations.

Claims 22, 30, 84, 86, 91, 93 and 94 are rejected under 35 U.S.C. 103(a) as being unpatentable over McCarty (US 5,073,374) in view of Streisand et al. (Buccal absorption of fentanyl is pH-dependent in dogs', *Anesthesiology*, (1995 Mar), 82 (3), pp. 759-64) and further in view of Gazzaniga et al. (U.S. 4,689,218).

McCarty teaches fast dissolving buccal tablets useful for the administration of active ingredients that include analgesics such as fentanyl as discussed above.

McCarty does not teach the at least one pH adjusting substance which is a base as claimed in claim 22 of the instant application.

Streisand et al. teach that the buccal absorption, bioavailability and permeability of fentanyl are pH dependent and increase as the pH of the fentanyl solution becomes more basic as discussed above.

It would have been prima facie obvious to one having ordinary skill in the art at the time the invention was made to modify the teachings of McCarty such as to adjust the pH to increase the buccal absorption of fentanyl. One having ordinary skill in the art would have been motivated to do this to obtain basic pH as which the buccal absorption, bioavailability and permeability of fentanyl increase, thus making the tablet more effective, as suggested by Streisand et al.

Streisand does not teach the effervescent couple of the instant claims.

Gazzaniga et al. teaches effervescent tablets comprising ibuprofen and sodium or potassium bicarbonate (20-35%) and sodium bitartrate (25-50%) (see Abstract). The reference further teaches that effervescent ibuprofen show a very good tolerability on the level of both oral and gastric mucosa and allow a faster absorption with a consequently faster analgesic effect and the analgesic effect begins in advance and lasts for a longer period of time (col. 3, lines 31-37, 53-55).

It would have been obvious to one of ordinary skill in the art at the time of the invention to add effervescent couple to an analgesic such as fentanyl. The motivation to do so is provided by Gazzaniga et al. The reference teaches the ibuprofen (analgesic) effervescent tablet absorption was faster with a consequently faster analgesic effect and the analgesic effect begins in advance and lasts for a longer period of time. It would have been obvious to one of ordinary skill in the art at the time of the invention to add

Art Unit: 1617

effervescent couple to analgesic such as fentanyl because Gazzaniga et al has shown the beneficial effects of effervescent analgesic (ibuprofen) namely faster absorption, faster analgesic effect and tolerability in oral mucosa. With respect to Claims 93 and 94, which recite tablet "adapted for" gingival and sublingual administration, respectively, these types of administration are obvious variations of oral transmucosal administration. Therefore, Claims 93 and 94 don't recite any additional ingredients and/or characteristics, therefore, the combination of references discussed above meets the claimed limitations.

Response to Arguments

Applicant's arguments with respect to claims 22, 25-27, 30-33, 83, 84, 86, 88, 91, 93 and 94 have been considered but are not persuasive. Please see response to arguments in the office action dated 07/28/2006. Applicants' argue pH proposed by Streisand is insufficient to achieve a significant benefit in the oral transmucosal permeability of fentanyl. In response, Streisand clearly teaches that buccal absorption of fentanyl is pH dependent and the absorption, bioavailability and permeability of fentanyl are markedly increased as the pH of the fentanyl solution becomes more basic, which is due to an increase in the fraction of unionized fentanyl. One of ordinary skill in the art at the time of the invention would be motivated to increase the buccal absorption, bioavailability and permeability of fentanyl by increasing the pH by routine experimentation. Wehling et al. teaches the use of the effervescent agents in analgesic formulations to provide disintegration of the tablet. It would have been obvious to one of ordinary skill in the art to combine teachings of McCarty, Wehling and Streisand to

Art Unit: 1617

make a composition comprising fentanyl, pH adjusting agent and effervescent couple as the prior art clearly teaches the buccal administration of fentanyl and Streisand teaches that adjusting pH increases absorption, bioavailability and permeability of fentanyl and Wehling teaches the disintegration of effervescent tablets.

Conclusion

No claim is allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Umamaheswari Ramachandran whose telephone number is 571-272-9926. The examiner can normally be reached on M-F 8:30 AM - 5:00 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreeni Padmanabhan can be reached on 571-272-0629. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.


SREENI PADMANABHAN
SUPERVISORY PATENT EXAMINER